Charts

Investors in Cassava Sciences Inc (SAVA) saw new options begin trading today, for the May 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new May 5th contracts and identified one put and one call contract of particular interest.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard ESG US.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cassava Sciences Inc (SAVA), where a total of 6,057 contracts have traded so far, representing approximately 605,700 underlying shares. That amounts to about 77.3% of SAVA's average daily trading volume over the past month of 783,885 shares..

MAKR House launched its new brand Disco Jays, offering a range of diamond-infused and THCA diamond-encrusted pre-rolls. This week the ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Momentive Global Inc (MNTV), where a total volume of 17,482 contracts has been traded thus far today, a contract volume which is representative of approximately 1.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 126.8% of MNTV's average daily trading volume over the past month, of 1.4 million shares..

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Asana (ASAN) stock is on the rise Thursday as investors react to the CEO share purchase plans and its latest earnings report. The post Why Is Asana (ASAN) Stock Up 24% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Etsy (ETSY) stock is falling on Thursday after the e-commerce company's shares were hit with a double downgrade from Jefferies. The post ETSY Stock Falls on Double Downgrade appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These three short-squeeze stocks are each options investors may want to consider as companies with near-term catalysts that could run. The post 3 Short-Squeeze Stocks to Keep on Your Radar appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. The post Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Biophytis S.A. (NASDAQ: BPTS) rose 56.3% to $0.7895 in pre-market trading after the company said it presents positive ...

Major U.S. indices closed mixed on Wednesday after Federal Reserve Chair Jerome Powell concluded his second day of testimony before ...

Cassava SciencesInc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider ...

Gainers Avenue Therapeutics (NASDAQ:ATXI) stock increased by 26.9% to $1.32 during Wednesday's after-market session. Trading volume for ...

While Cassava Sciences, Inc. (NASDAQ:SAVA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 22%...

Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call

Investors in Cassava Sciences Inc (SAVA) saw new options become available today, for the April 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new April 14th contracts and identified one put and one call contract of particular interest.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cassava Sciences Inc (SAVA), where a total volume of 4,683 contracts has been traded thus far today, a contract volume which is representative of approximately 468,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.6% of SAVA's average daily trading volume over the past month, of 1.1 million shares..

In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease.Mid-year 2023, We Expect an Independent Third Party to Present Evidential Data for The Biological Activity of Simufilam Outside of Neurodegeneration.Cash And Cash Equivalents Were $201 Million at Decemb

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch. The post 3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $284.04 per unit.

953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia. Simufilam, an o

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Rocket Companies Inc Class A (RKT), where a total of 22,882 contracts have traded so far, representing approximately 2.3 million underlying shares. That amounts to about 80% of RKT's average daily trading volume over the past month of 2.9 million shares..

It isn't about running out of money, but it's still laden with risk.

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 27.78% on an annualized basis producing an average ...

Shares in cybersecurity firm Darktrace fell as much as 7% in Tuesday London trading after short seller Quintessential Capital Management put out a report explaining its newly disclosed short position.

Investors did not like the latest update from Alzheimer's drug maker Cassava Sciences (NASDAQ:SAVA). After showing excellent results from the first 50 patients treated with simufilam, the company's prospective Alzheimer’s drug in an open-label mid-stage study, the results from the full 200+ patients were not as good. Patients were given 2 100mg tablets a day over the course of one year on average, and these exhibited only a minimal change in the ADAS-Cog score. In the clinical research of Alzhei

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in MicroStrategy Inc. (MSTR), where a total volume of 15,809 contracts has been traded thus far today, a contract volume which is representative of approximately 1.6 million underlying shares (given that every 1 contract represents 100 underlying shares)..

Major Wall Street indices closed mixed on Tuesday as a disparateset of corporate earnings dampened the existing euphoria over the ...

Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall. The post Why Is Cassava Sciences (SAVA) Stock Down 20% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Cassava SciencesInc (NASDAQ: SAVA) shares are trading significantly lower Tuesday after the company announced top-line clinical ...

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim ...

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 115.1% to $3.42 during Tuesday's regular session. Trading volume for ...

Cassava Sciences Inc(NASDAQ: SAVA) announcedtopline Phase 2 resultsfor simufilam, its oral drug candidate for ...

Editor's note: The headline of this story has been updated to more accurately reflect the results of the Cassava Sciences Phase 2 trial for simufilam. Cassava Sciences Inc (NASDAQ: SAVA) announced topline Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. Study participants were administered open-label simufilam tablets 100mg twice daily for one year or more. Endpoints were measured at baseline (study entry) and month 12. In the mild sub-group, ADAS-Cog (cog

U.S. stocks traded mostly higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording losses in ...

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening ...

Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point

Investors in Cassava Sciences Inc (SAVA) saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 27.31% on an annualized basis producing an average ...

Cassava Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 87.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Signature Bank (SBNY), where a total of 14,803 contracts have traded so far, representing approximately 1.5 million underlying shares. That amounts to about 129.3% of SBNY's average daily trading volume over the past month of 1.1 million shares..

Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock. The post Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OneMain Holdings Inc (OMF), where a total of 12,467 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 99.9% of OMF's average daily trading volume over the past month of 1.2 million shares..

Stocks of companies with Alzheimer's candidates, includingCassava Sciences, Inc.(NASDAQ: SAVA) andEli Lilly And ...

If you want to know who really controls Cassava Sciences, Inc. (NASDAQ:SAVA), then you'll have to look at the makeup of its share registry...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cassava Sciences Inc (SAVA), where a total volume of 8,430 contracts has been traded thus far today, a contract volume which is representative of approximately 843,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 65.2% of SAVA's average daily trading volume over the past month, of 1.3 million shares..

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Micron Technology Inc. (MU), where a total volume of 281,030 contracts has been traded thus far today, a contract volume which is representative of approximately 28.1 million underlying shares (given that every 1 contract represents 100 underlying shares)..

Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after ...

Investors in Cassava Sciences Inc (SAVA) saw new options become available this week, for the August 2023 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passing of a cherished colleague and friend,” said Remi Barbier, President and CEO. “For over 20 years, he generously gave his talents, expertise and integrity in support of our success. On behalf of our employees and our

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Boston Beer Co Inc (SAM), where a total volume of 602 contracts has been traded thus far today, a contract volume which is representative of approximately 60,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 66.5% of SAM's average daily trading volume over the past month, of 90,460 shares..

It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here's why SAVA stock may rise even more soon. The post Why Is Cassava Sciences (SAVA) Stock Up 10% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cassava Sciences Inc (SAVA), where a total of 14,543 contracts have traded so far, representing approximately 1.5 million underlying shares. That amounts to about 107.1% of SAVA's average daily trading volume over the past month of 1.4 million shares..

Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzhe

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading

AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer

High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal. Categories include bribery, fraud, stock manipulation, and even non-criminal charges, such as negligent and strict liability torts. In some cases, the “sca

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k